Cargando…

Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial

INTRODUCTION: Exercise limitation, dynamic hyperinflation, and exertional dyspnea are key features of symptomatic chronic obstructive pulmonary disease (COPD). We assessed the effects of glycopyrronium bromide (NVA237), a once-daily, long-acting muscarinic antagonist, on exercise tolerance in patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beeh, Kai M, Singh, Dave, Di Scala, Lilla, Drollmann, Anton
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3430121/ https://www.ncbi.nlm.nih.gov/pubmed/22973092 http://dx.doi.org/10.2147/COPD.S32451

Ejemplares similares

Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial
por: D'Urzo, Anthony, et al.
Publicado: (2011)

Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD
por: D’Urzo, Anthony
Publicado: (2013)

Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study
por: Kerwin, Edward, et al.
Publicado: (2012)

A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study
por: Chapman, Kenneth R, et al.
Publicado: (2014)

Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
por: Vincken, Walter, et al.
Publicado: (2014)

Indacaterol: a new once daily long-acting beta(2) adrenoceptor agonist
por: Beeh, Kai M, et al.
Publicado: (2010)

Pharmacodynamics and Pharmacokinetics Following Once-Daily and Twice-Daily Dosing of Tiotropium Respimat(®) in Asthma Using Standardized Sample-Contamination Avoidance
por: Beeh, Kai-Michael, et al.
Publicado: (2016)

Once-daily dosing of gentamicin.
por: Soper, D E
Publicado: (1998)

Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study
por: Wang, Chen, et al.
Publicado: (2015)

Is once enough? Understanding the preferences of COPD and asthma patients for once- versus twice-daily treatment
por: Horne, Rob
Publicado: (2013)

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD
por: Buhl, Roland, et al.
Publicado: (2012)

CoNVaQ: a web tool for copy number variation-based association studies
por: Larsen, Simon Jonas, et al.
Publicado: (2018)

The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects
por: Derom, Eric, et al.
Publicado: (2019)

The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study)
por: Beeh, Kai-Michael, et al.
Publicado: (2016)

Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study [Corrigendum]
Publicado: (2015)

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD [Corrigendum]
Publicado: (2014)

Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study
por: Church, Alison, et al.
Publicado: (2014)

Differences in Pulmonary Function Improvement after Once-Daily LABA/LAMA Fixed-Dose Combinations in Patients with COPD
por: Huang, Wei-Chun, et al.
Publicado: (2022)

Long-Term Effectiveness, Safety, and Tolerability of Twice-Daily Dosing with Deferasirox in Children with Transfusion-Dependent Thalassemias Unresponsive to Standard Once-Daily Dosing
por: Buaboonnam, Jassada, et al.
Publicado: (2021)

The use of once-daily dosing of gentamicin in obstetrics and gynecology.
por: Wiesenfeld, H C, et al.
Publicado: (1998)

Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD
por: Donohue, James F, et al.
Publicado: (2019)

Once‐ and twice‐daily heat acclimation confer similar heat adaptations, inflammatory responses and exercise tolerance improvements
por: Willmott, Ashley G. B., et al.
Publicado: (2018)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications
por: Shen, Jie, et al.
Publicado: (2017)

The pharmacokinetics of once-daily dosing with gentamicin in women with postpartum endometritis.
por: Sunyecz, J A, et al.
Publicado: (1998)

Chronopharmacokinetics of once daily dosed aminoglycosides in hospitalized infectious patients
por: van Maarseveen, Erik, et al.
Publicado: (2015)

SPOTlight on GLOW
por: Derks, Sarah, et al.
Publicado: (2023)

Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life
por: Tabberer, Maggie, et al.
Publicado: (2018)

Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial
por: Ismaila, Afisi S, et al.
Publicado: (2019)

Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β(2)-agonist, in patients with asthma: results of a parallel-group study and a crossover study
por: O’Byrne, Paul M., et al.
Publicado: (2015)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications [Corrigendum]
Publicado: (2018)

A randomized trial of once daily versus twice daily dosing of oral iron in CKD
por: Sood, Vivek, et al.
Publicado: (2023)

Tolerability and safety of gastroretentive once-daily gabapentin tablets for the treatment of postherpetic neuralgia
por: Irving, Gordon A, et al.
Publicado: (2012)

Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple Therapy in Spain: IMPACT Trial
por: Paly, Victoria Federico, et al.
Publicado: (2022)

Efficacy and safety of once daily dosing of colistin to critically ill patients
por: Skiada, A, et al.
Publicado: (2010)

A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy
por: Washington, Samuel L, et al.
Publicado: (2010)

SUN-237 Sex Differences in the Effect of Osteocalcin and Exercise on Memory and Cognition
por: Winberg, Jordan, et al.
Publicado: (2020)

Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study
por: Buhl, Roland, et al.
Publicado: (2015)

The Effect of Fatigue and Fatigue Intensity on Exercise Tolerance in Moderate COPD
por: Al-shair, Khaled, et al.
Publicado: (2016)

Once-daily dose regimen of ribavirin is interchangeable with a twice-daily dose regimen: randomized open clinical trial
por: Balk, Jiska M, et al.
Publicado: (2015)

Tacrolimus dose adjustment is not necessary in dose to dose conversion from a twice daily to a prolonged release once daily dose form
por: Tiankanon, Kanitha, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_57f0udglaap29s1rsbf6m4f6th